Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture.
This week Lewis Goldberg and Anne Donohoe are back for a new episode with special guest Nathan Bryson, PhD, Chief Scientific Officer of Reunion Neuroscience. Nathan joins us this week to discuss how he made his way to Reunion, the company’s unique serotonergic psychedelic compound that’s situated between psilocybin and DMT and designed to treat postpartum depression, goals of the neuroscience company and what he finds most intriguing about the discovery, creation and pathway to bringing novel compounds to market.
If you are interested in learning more about Reunion or following the company’s research and development progress, visit the links in our show notes. Also, be sure to follow Nathan and Reunion on LinkedIn, Twitter and Instagram.
So sit back and enjoy our conversation with Nathan Bryson of Reunion Neuroscience.
Links and mentions in the show
https://reunionneuro.com/
Links to the guest’s company and social media accounts
Reunion Neuroscience’s Twitter: https://twitter.com/ReunionNeuro
Reunion Neuroscience’s LinkedIn: https://www.linkedin.com/company/reunionneuro
Reunion Neuroscience’s Instagram: https://www.instagram.com/reunionneuro/
Nathan’s LinkedIn: https://www.linkedin.com/in/nathanbryson/
Show Credits:
This episode was hosted by Lewis Goldberg and Anne Donohoe of KCSA Strategic Communications.
Special thanks to our Program Director Shea Gunther.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels:
Twitter: @The_GreenRush
Instagram: @thegreenrush_podcast
LinkedIn: https://www.linkedin.com/company/thegreenrushpodcast/
Facebook: https://www.facebook.com/TheGreenRushPodcast/
YouTube: https://www.youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true
